Breaking News

Sirona Biochem, Biogalenys in Glycoprotein Pact

July 3, 2013

To study cell preservation technology

Sirona Biochem Corp. has signed a Letter of Intent (LOI) to collaborate with Biogalenys to study Sirona's glycoprotein (cell preservation) technology and to develop preclinical data for multiple targeted applications.
Potential applications for Sirona’s cell preservation technology include anti-aging cream, sunscreen/UV protection, wound care, reduced scarring, frostbite protection, stem cell preservation, beta islet cell preservation, platelet and red blood cell preservation, and increased preservation times for tissue explants and organ transplantation. The three-year collaboration will initially study the technology in cosmetic anti-aging active ingredient and as a preservative adjuvant for tissue explants.
"We are excited to be creating a second project partnership with Biogalenys,” said Neil Belenkie, chief executive officer of Sirona Biochem. "We look forward to continuing the success that our companies achieved on our skin lightening project; applying our shared expertise in the study and development of our new cell preservation technology.”
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.